The Pharma Data

NOVEMBER 4, 2020

Bactiguard’s growth strategy for the coming five-year period up to 2025 is based on a continued roll-out of Bactiguard’s technology, with a focus on new license agreements and a broader product portfolio. We have several interesting licensing projects ongoing and see new, exciting business opportunities.

Licensing 52

Licensing Licensing Production Marketing 52

The Pharma Data

NOVEMBER 29, 2020

1 Meanwhile, these MDM2 inhibitors present some challenges, including dose-limiting hematological toxicities, thus the urgent need to develop new generation of MDM2-targeting therapies in the treatment of cancer. View original content to download multimedia: [link]. SUZHOU, China and ROCKVILLE, Md. , ” References: Zhao, Y.;

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

Drug Channels

OCTOBER 19, 2020

You can download the complete agenda here. Medical Plus – Tailored Track Options Based on Company Size : Emerging/Small Companies – Infrastructure Set-Up, License Procurement and 3PL Contracting Mid-Large Companies – How Do I Think About My Portfolio Differently Based on Product Type?

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Licensing 52

The Pharma Data

NOVEMBER 25, 2020

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. About BioInvent. SOURCE BioInvent.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

OCTOBER 27, 2020

We are pleased to see more vision-saving therapies moving toward clinical trials and potentially out to the people who urgently need them,” says Brian Mansfield , PhD, executive vice president research, interim chief scientific officer of the Foundation Fighting Blindness. RIDGEWOOD, N.J. ,

Disease 52

Disease Treatment FDA Licensing 52

The Pharma Data

DECEMBER 21, 2020

UBX1325 is developed from BM-962, a Bcl-xL inhibiting compound licensed to UNITY by Ascentage Pharma for the treatment of age-related diseases. This progress in clinical development qualifies Ascentage Pharma for a milestone payment according to the terms of the licensing agreement. View original content to download multimedia: [link].

Clinical Development 40

Clinical Development Disease Treatment Licensing 40

The Pharma Data

DECEMBER 8, 2020

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. About BioInvent. www.bioinvent.com.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

NOVEMBER 24, 2020

Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. This information was brought to you by Cision [link].

FDA 40

FDA Clinical Trials Drugs Therapies 40

The Pharma Data

JANUARY 19, 2021

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with three ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. About BioInvent. SOURCE BioInvent.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

JANUARY 27, 2021

. A total of 15 patients have been recruited to date in the Phase I dose escalation part of the study, all of whom were late stage and have failed conventional treatments, including several lines of rituximab-containing therapies. View original content to download multimedia: [link].

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 13, 2021

At Usona, Mr. Barrow was responsible for launching the Phase 2 clinical program for psilocybin in the treatment of Major Depressive Disorder and for obtaining Breakthrough Therapy Designation for the program at FDA. View original content to download multimedia: [link]. MindMed Co-CEO J.R.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

JANUARY 7, 2021

RMI), a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox , will present at the 39th Annual J.P. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. SAN MATEO, Calif. ,

Clinical Trials 52

Clinical Trials Therapies Trials Licensing 52

The Pharma Data

NOVEMBER 25, 2020

is an innovative, science-driven pharmaceutical company focused on novel therapies for a variety of indications. View original content to download multimedia: [link]. . Vivera Pharmaceuticals, Inc., . SOURCE Vivera Pharmaceuticals, Inc. Source link.

Pharmaceuticals 52

Pharmaceuticals Hospitals Pharmaceutical Companies Licensing 52

The Pharma Data

JANUARY 10, 2021

Depending on the development of the escalating COVID-19 pandemic in the United States and on the resulting impact on enrollment, the Company expects to complete enrollment of this study in 2022 enabling a potential Biologics License Application (BLA) submission by 2023 under the accelerated approval pathway. SOURCE Hansa Biopharma AB.

Therapies 52

Therapies Treatment Trials Disease 52

The Pharma Data

OCTOBER 29, 2020

“Patients with alopecia areata deal with unpredictable and long-lasting episodes of hair loss and many don’t find relief from the therapies that are currently used,” said Lotus Mallbris, M.D., Baricitinib, an oral JAK1/JAK2 inhibitor discovered by Incyte, is developed by Lilly under license from Incyte.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

A preprint supporting Brilacidin’s COVID-19 treatment potential can be downloaded at the link below. Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. Global COVID-19 Cases and Mortality An online tool tracking COVID-19 cases and mortality, both in the U.S.

Clinical Trials 52

Clinical Trials Trials Treatment FDA 52

The Pharma Data

DECEMBER 20, 2020

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four programs in clinical development. The following files are available for download: View original content: [link]. SOURCE BioInvent. Source link.

Virus 52

Virus Trials Clinical Trials Clinical Development 52

The Pharma Data

NOVEMBER 26, 2020

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. About BioInvent. SOURCE BioInvent.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. View original content to download multimedia: [link].

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

NOVEMBER 26, 2020

Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for review of the Company’s Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa (PRX–102) for the proposed treatment of adult patients with Fabry disease. Protalix has licensed to Pfizer Inc.

Disease 52

Disease Treatment Clinical Trials FDA 52

The Pharma Data

DECEMBER 30, 2020

31, 2020 /PRNewswire/ — ImmVira Group Company (“the Company”), a biotechnology platform dedicated to the development of oncolytic virus(“OV”) and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C financing. .

Virus 52

Virus International Trials Clinical Trials 52

The Pharma Data

JANUARY 27, 2021

Finalized the technical development of modia , a digital therapy for opioid use disorder, for which Orexo owns the exclusive global rights. Entered an exclusive license and supply agreement with Accord Healthcare for ZUBSOLV® covering 29 European countries. Important events after the period.

Therapies 52

Therapies Production Treatment FDA 52

The Pharma Data

MAY 15, 2021

When I graduated from Ohio State University in 1996 with a Bachelors of Science degree of Physical Therapy, I walked away with the collective knowledge of 1,000’s of doctors and scientists on how the body’s joints and muscles grow, heal, and sustain themselves. So why should you put your shoulder’s health in my hands?

Production 52

Production Doctors Therapies Science 52

The Pharma Data

JANUARY 31, 2021

Importantly, the negative pressure component of each acoustic pulse is attenuated so therapy can be provided without creating cavitation or heating that could result in surrounding tissue damage. View original content to download multimedia: [link]. About Soliton, Inc. Soliton, Inc.

FDA 52

FDA Treatment Clinical Trials Licensing 52

The Pharma Data

DECEMBER 16, 2020

The Company will initiate its trial during the first quarter of 2021 to investigate the efficacy of Berubicin in adults with GBM who have failed first-line therapy. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. .

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

NOVEMBER 10, 2020

AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is extremely limited. [link].

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

The Pharma Data

JANUARY 18, 2021

In-licensed from Merck KGaA, Darmstadt, Germany , atacicept has been studied previously in autoimmune diseases and shown to reduce autoantibodies in a dose-dependent fashion with once-weekly subcutaneous dosing and has a well-established and acceptable clinical safety profile. .” View original content to download multimedia: [link].

Disease 52

Disease Science Clinical Development Treatment 52

The Pharma Data

NOVEMBER 2, 2020

If approved, 1st Therapy in U.S. Europe, Latin America, the Middle East, and most of Asia Pacific, there are currently no licensed medicines for achondroplasia. BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases.

Drugs 40

Drugs FDA Treatment Pharmaceuticals 40

The Pharma Data

MAY 15, 2021

“WARNING: Common Drugs And Therapies Used To Treat CFS & Its Symptoms Can Have Serious Side Effects” Conventional drugs can have a myriad of side effects and are not effective at treating CFS from its roots. Once you’ve downloaded your book, read the entire guide and start immediately! Alisha Smith.

Doctors 52

Doctors Production Therapies Treatment 52

The Pharma Data

OCTOBER 28, 2020

Wenger, a licensed counselor and senior training and consultation specialist at the Mental Health Technology Transfer Center at Rutgers University in Piscataway, N.J. Teens can also download apps for meditation or mindfulness, Gurwitch said. . “Teenage years are when kids don’t want their parents around. More information.

Licensing 40

Licensing Licensing Therapies 40

The Pharma Data

SEPTEMBER 16, 2020

Additionally, data from Amgen ‘s bispecific T cell engager (BiTE ® ) platform will feature preliminary safety and efficacy findings from the ongoing Phase 1 study of AMG 160, an investigational half-life extended BiTE immuno-oncology therapy targeting prostate-specific membrane antigen (PSMA). 20 and AMG 160, Monday Sept. Reese , M.D.,

Clinical Trials 52

Clinical Trials Production Trials Government 52

The Pharma Data

SEPTEMBER 20, 2020

and 91.2%, respectively, in 34 heavily pretreated patients (median of two prior lines of therapy) with NSCLC, who were treated with the 960 mg daily dose (data cutoff of June 1 , 2020). Eligible patients must have received a prior line of systemic anticancer therapy, consistent with their tumor type and stage of disease. Reese , M.D.,

Clinical Trials 52

Clinical Trials Production Trials Government 52

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). View original content to download multimedia: [link]. million and US$1.8

Licensing 40

Licensing Licensing Production Engineering 40

The Pharma Data

OCTOBER 14, 2020

14, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the U.S. PLYMOUTH MEETING, Pa. and CHICAGO , Oct.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

Agency IQ

MAY 10, 2024

The agencies have also worked together on topics such standardization in digital imaging and medical displays and cell and gene therapy manufacturing. GAI systems may infringe on copyrighted or trademarked content, trade secrets, or other licensed content,” which are “often” part of the training data sets.

Science 40

Science FDA Production Regulations 40

PerkinElmer

JUNE 7, 2021

Targeted cancer therapy has been a game changer in cancer treatment, significantly improving the survival and quality of life of many patients. Unlike chemotherapy, which acts on both cancer and normal cells, targeted therapy affects only the specific oncogenes, tumor suppressor genes, or pathways involved in tumor progression.

Treatment 52

Treatment Clinical Trials Therapies Trials 52

The Pharma Data

JANUARY 21, 2021

Prior to initiating treatment with CABENUVA, oral cabotegravir (VOCABRIA) and oral rilpivirine (EDURANT ® ) should be administered for approximately one month to assess the tolerability of each therapy. Trademarks are owned by or licensed to Janssen and the ViiV Healthcare group of companies. 50 c/mL, meeting noninferiority criteria.

FDA Approval 52

FDA Approval Treatment RNA FDA 52